Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Extrafine triple therapy … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA

Artikel i vetenskaplig tidskrift
Författare D. Singh
Leonardo M. Fabbri
S. Vezzoli
S. Petruzzelli
A. Papi
Publicerad i International journal of chronic obstructive pulmonary disease
Volym 14
Sidor 531-546
ISSN 1178-2005
Publiceringsår 2019
Publicerad vid Institutionen för medicin
Sidor 531-546
Språk en
Länkar dx.doi.org/10.2147/copd.S196383
Ämnesord anticholinergics, beta-2 agonists, chronic obstructive pulmonary disease, disease activity, inhaled, obstructive pulmonary-disease, lung-function decline, post-hoc analysis, exacerbation frequency, pooled analysis, parallel-group, double-blind, indacaterol/glycopyrronium, hospitalization, prevention
Ämneskategorier Lungmedicin och allergi

Sammanfattning

Background: Current pharmacological therapies for COPD improve quality of life and symptoms and reduce exacerbations. Given the progressive nature of COPD, it is arguably more important to understand whether the available therapies are able to delay clinical deterioration; the concept of "clinically important deterioration" (CID) has therefore been developed. We evaluated the efficacy of the single-inhaler triple combination beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G), using data from three large 1-year studies. Methods: The studies compared BDP/FF/G to BDP/FF (TRILOGY), tiotropium (TRINITY), and indacaterol/glycopyrronium (IND/GLY; TRIBUTE). All studies recruited patients with symptomatic COPD, FEV1 < 50%, and an exacerbation history. We measured the time to first CID and to sustained CID, an endpoint combining FEV1, St George's Respiratory Questionnaire (SGRQ), moderate-to-severe exacerbations, and death. The time to first CID was based on the first occurrence of any of the following: a decrease of >= 100 mL from baseline in FEV1, an increase of >= 4 units from baseline in SGRQ total score, the occurrence of a moderate/severe COPD exacerbation, or death. The time to sustained CID was defined as: a CID in FEV1 and/or SGRQ total score maintained at all subsequent visits, an exacerbation, or death. Results: Extrafine BDP/FF/G significantly extended the time to first CID vs BDP/FF (HR 0.61, P < 0.001), tiotropium (0.72, P < 0.001), and IND/GLY (0.82, P < 0.001), and significantly extended the time to sustained CID vs BDP/FF (HR 0.64, P < 0.001) and tiotropium (0.80, P < 0.001), with a numerical extension vs IND/GLY. Conclusion: In patients with symptomatic COPD, FEV1 < 50%, and an exacerbation history, extrafine BDP/FF/G delayed disease deterioration compared with BDP/FF, tiotropium, and IND/GLY.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?